Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
The Lancet（2022）
摘要
Merck Sharp & Dohme.
更多查看译文
关键词
refractory chronic cough,unexplained chronic cough,p2x3 receptor antagonist,gefapixant,efficacy,double-blind,parallel-group,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要